Eton Pharmaceuticals licenses Increlex rights abroad

DEER PARK, Ill. - Eton Pharmaceuticals, Inc (NASDAQ:ETON), a company specializing in rare disease treatments with a market capitalization of $348 million and an impressive 246% return over the past year, has announced the out-licensing of Increlex® commercial rights outside the U.S. to Esteve Pharmaceuticals, S.A. The deal, effective immediately, allows Esteve to market and distribute the drug in international markets for up to ten years, with an option to acquire the rights in the future. According to InvestingPro data, the company’s strong market performance reflects growing investor confidence in its business model.

Sean Brynjelsen, CEO of Eton Pharmaceuticals, stated that partnering with Esteve will enable Eton to concentrate on its U.S. growth opportunities, including three rare disease product launches planned for 2025. The agreement is expected to streamline Eton’s operations by reducing the need for substantial infrastructure investments for international commercialization efforts.

Eton will continue to supply Increlex to Esteve at a predetermined transfer price. According to Eton’s projections, this arrangement will not affect the company’s anticipated $80 million annual revenue run rate by the end of 2025.

Eton’s portfolio currently includes seven commercial products targeting rare diseases, with six additional candidates in late-stage development. The company’s strategy focuses on developing and commercializing innovative treatments, with an emphasis on patient care and accessibility.

The financial terms of the deal have not been disclosed, and Eton’s forward-looking statements are based on expectations that may change due to various risks and uncertainties. This press release statement serves as the basis for the information reported here.

In other recent news, Eton Pharmaceuticals has reported its fourth-quarter 2024 financial results, emphasizing its strategy to expand its product portfolio and advance its internal pipeline. The company is preparing for the mid-2025 launch of ET-400, a hydrocortisone oral solution, pending FDA approval, which is expected to contribute significantly to future revenues. Eton also announced the successful completion of a pivotal bioequivalence study for ET-600, an oral solution of desmopressin, with plans to submit a New Drug Application to the FDA in April 2025. This would make ET-600 the only FDA-approved oral liquid formulation of desmopressin, addressing a critical need in the pediatric endocrinology community.

Additionally, Eton has launched Galzin® capsules for Wilson disease treatment, with a focus on enhancing patient access through the Eton Cares program. Analyst firm H.C. Wainwright has adjusted its price target for Eton to $33.00, maintaining a Buy rating, citing the company’s strategic initiatives and projected revenue growth. B.Riley has also initiated coverage with a Buy rating and a $21.00 price target, highlighting Eton’s potential profitability in 2025 driven by products like Increlex and ET-400. Eton’s CEO, Sean Brynjelsen, expressed optimism about the company’s progress and future product launches. These developments underscore Eton’s commitment to advancing treatment options for rare diseases and achieving its financial goals.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.